Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Subscribe To Our Newsletter & Stay Updated